Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Indivior PLC stock logo
INDV
Indivior
$22.85
-1.4%
$23.00
$7.33
$25.10
$3.16B0.71.88 million shs328,509 shs
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
$33.18
+8.2%
$25.25
$14.06
$34.62
$3.74B0.02892,037 shs1.12 million shs
Rezolute, Inc. stock logo
RZLT
Rezolute
$9.00
-1.1%
$7.31
$2.21
$9.72
$822.19M0.04986,688 shs296,409 shs
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$10.20
-0.8%
$10.82
$8.93
$30.36
$3.45BN/A76,711 shs25,107 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Indivior PLC stock logo
INDV
Indivior
0.00%-3.14%-7.25%+49.00%+122.36%
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
0.00%+7.61%+13.59%+57.61%+68.33%
Rezolute, Inc. stock logo
RZLT
Rezolute
0.00%-2.57%+13.75%+82.73%+84.58%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
0.00%+3.01%+13.47%-33.59%+1,027,999,900.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Indivior PLC stock logo
INDV
Indivior
$22.85
-1.4%
$23.00
$7.33
$25.10
$3.16B0.71.88 million shs328,509 shs
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
$33.18
+8.2%
$25.25
$14.06
$34.62
$3.74B0.02892,037 shs1.12 million shs
Rezolute, Inc. stock logo
RZLT
Rezolute
$9.00
-1.1%
$7.31
$2.21
$9.72
$822.19M0.04986,688 shs296,409 shs
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$10.20
-0.8%
$10.82
$8.93
$30.36
$3.45BN/A76,711 shs25,107 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Indivior PLC stock logo
INDV
Indivior
0.00%-3.14%-7.25%+49.00%+122.36%
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
0.00%+7.61%+13.59%+57.61%+68.33%
Rezolute, Inc. stock logo
RZLT
Rezolute
0.00%-2.57%+13.75%+82.73%+84.58%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
0.00%+3.01%+13.47%-33.59%+1,027,999,900.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Indivior PLC stock logo
INDV
Indivior
3.00
Buy$22.00-3.74% Downside
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
2.70
Moderate Buy$42.0026.58% Upside
Rezolute, Inc. stock logo
RZLT
Rezolute
2.88
Moderate Buy$14.5061.13% Upside
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
2.57
Moderate Buy$21.00105.98% Upside

Current Analyst Ratings Breakdown

Latest RZLT, TLX, INDV, and NAMS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/27/2025
Indivior PLC stock logo
INDV
Indivior
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C-)
9/27/2025
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/27/2025
Rezolute, Inc. stock logo
RZLT
Rezolute
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/27/2025
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D)
9/23/2025
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$23.00 ➝ $20.00
9/22/2025
Rezolute, Inc. stock logo
RZLT
Rezolute
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$15.00
9/18/2025
Rezolute, Inc. stock logo
RZLT
Rezolute
Maxim Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$15.00 ➝ $20.00
9/18/2025
Rezolute, Inc. stock logo
RZLT
Rezolute
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$12.00
9/18/2025
Rezolute, Inc. stock logo
RZLT
Rezolute
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$17.00
9/18/2025
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$22.00
9/10/2025
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$23.00 ➝ $20.00
(Data available from 10/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Indivior PLC stock logo
INDV
Indivior
$1.17B2.69$1.80 per share12.73($2.52) per share-9.07
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
$64.01M58.39N/AN/A$8.20 per share4.05
Rezolute, Inc. stock logo
RZLT
Rezolute
N/AN/AN/AN/A$1.86 per shareN/A
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$516.72M6.68$0.11 per share90.02$1.12 per share9.10
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Indivior PLC stock logo
INDV
Indivior
$2M$0.6237.0013.36N/A6.65%-86.28%16.26%10/23/2025 (Estimated)
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
-$241.60M-$1.62N/AN/AN/A-259.07%-27.27%-25.00%11/5/2025 (Estimated)
Rezolute, Inc. stock logo
RZLT
Rezolute
-$74.41M-$0.97N/AN/AN/AN/A-65.03%-58.86%11/6/2025 (Estimated)
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$32.93MN/A0.0021.24N/AN/AN/AN/AN/A

Latest RZLT, TLX, INDV, and NAMS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/23/2025Q3 2025
Indivior PLC stock logo
INDV
Indivior
$0.38N/AN/AN/AN/AN/A
9/17/2025Q4 2025
Rezolute, Inc. stock logo
RZLT
Rezolute
-$0.23-$0.26-$0.03-$0.26N/AN/A
8/6/2025Q2 2025
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
-$0.52-$0.15+$0.37-$0.15$1.44 million$19.15 million
7/31/2025Q2 2025
Indivior PLC stock logo
INDV
Indivior
$0.26$0.51+$0.25$0.14$239.43 million$302.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Indivior PLC stock logo
INDV
Indivior
N/AN/AN/AN/AN/A
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
N/AN/AN/AN/AN/A
Rezolute, Inc. stock logo
RZLT
Rezolute
N/AN/AN/AN/AN/A
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Indivior PLC stock logo
INDV
Indivior
N/A
0.90
0.76
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
N/A
21.08
21.08
Rezolute, Inc. stock logo
RZLT
Rezolute
N/A
14.37
14.37
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Indivior PLC stock logo
INDV
Indivior
60.33%
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
89.89%
Rezolute, Inc. stock logo
RZLT
Rezolute
82.97%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/A

Insider Ownership

CompanyInsider Ownership
Indivior PLC stock logo
INDV
Indivior
N/A
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
20.84%
Rezolute, Inc. stock logo
RZLT
Rezolute
18.39%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Indivior PLC stock logo
INDV
Indivior
1,051137.88 millionN/ANot Optionable
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
4112.63 million89.16 millionOptionable
Rezolute, Inc. stock logo
RZLT
Rezolute
4090.81 million74.11 millionOptionable
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/A338.44 millionN/AN/A

Recent News About These Companies

CMS Grants Transitional Pass-Through Status for Gozellix

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Indivior stock logo

Indivior NASDAQ:INDV

$22.85 -0.32 (-1.36%)
As of 11:42 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

NewAmsterdam Pharma stock logo

NewAmsterdam Pharma NASDAQ:NAMS

$33.18 +2.51 (+8.18%)
As of 11:43 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Rezolute stock logo

Rezolute NASDAQ:RZLT

$9.00 -0.10 (-1.11%)
As of 11:42 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Telix Pharmaceuticals stock logo

Telix Pharmaceuticals NASDAQ:TLX

$10.20 -0.09 (-0.83%)
As of 11:42 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.